Genta Incorporated Announces Conference Call to Discuss First Quarter 2004 Earnings
BERKELEY HEIGHTS, N.J., April 27 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA) will host a conference call and live audio webcast
of its first quarter financial results on Thursday, April 29, 2004. William
P. Keane, Vice President and Chief Financial Officer will host the conference
call and live audio webcast at 8:30 AM EDT.
The conference call can be accessed live as follows:
U.S./Canada: Dial (877) 634-8606, reference Genta Incorporated.
International: Dial (706) 679-3140, reference Genta Incorporated.
The webcast will be available in the Investor Relations section of the
Company's website at: genta.com
and will be archived for 30 days.
About Genta
Genta Incorporated is a pharmaceutical company with a diversified product
portfolio that is focused on delivering innovative products for the treatment
of patients with cancer. The Company's research platform is anchored by two
major programs that center on oligonucleotides (RNA and DNA-based medicines)
and small molecules. Genasense(TM) (oblimersen sodium) Injection, the
Company's lead compound from its oligonucleotide program, is being developed
with Aventis and is currently undergoing late-stage, Phase 3 clinical testing.
The leading drug in Genta's small molecule program is Ganite(R) (gallium
nitrate injection), which the Company is exclusively marketing in the U.S. for
treatment of patients with cancer-related hypercalcemia that is resistant to
hydration. For more information about Genta, please visit our website at:
genta.com.
This press release and the conference call and webcast to follow contain
forward-looking statements with respect to business conducted by Genta
Incorporated. By their nature, forward-looking statements and forecasts
involve risks and uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number of factors
that could cause actual results and developments to differ materially. For a
discussion of those risks and uncertainties, please see the Company's Annual
Report/Form 10-K for 2002. |
